Claim 1: an immunoassay method to detect and quantify IL - 13, where the method is capable of detecting and quantifying il-13 in a sample with High Sensitivity and High specificity.Method 4: the claim of any of claims 1 - 3, where the method is a method of Sandwich immunoassay and comprises a First Capture monoclonal antibody that specifically binds with IL - 13 and a Second monoclonal antibody that binds specific detection Only with IL - 13, where the first Antibody binds to a different epitope of the second Antibody.Claim 19: a method for Predicting the response of a patient suffering from Asthma or a disease associated with Th2 to a Therapy that includes a Th2 Pathway Inhibitor, wherein the method comprises: obtaining a Biological sample from the patient, measure the level of IL - 13 using the method Any of claims 1 - 18Compare the level of il-13 was detected in the sample with a reference level, and predict that the patient will respond to Therapy when the level of il-13 measured in the sample is increased compared to the baseline, or predict that the patient does not respond to the therapy. L il-13 measured in the sample is reduced compared to the baseline.Claim 32: a method for treating a patient who has Asthma or a disease associated with Th2The Method comprises: (a) to measure the level of il-13 in a Biological sample from a patient using the method of any of claims 1 - 18 (b) comparing the level of il-13 measured in (a) with a reference level (c) identify the patient as one more probably respond To a Therapy that includes a Th2 Pathway inhibitor when the level of il-13 measured in (TO) thisAbove the baseline and (d) to administer the therapy when the level of il-13 measured in (a) is above the reference level, which is the Asthma or the disorder associated with Th2.Claim 72: a kit to stratify a patient with Asthma or a patient having a disease associated with Th2, where the Reagent Kit comprises: (a) to measure the level of il-13 in a sample obtained from t
